GlassScriptPhysician profile
Andrea Thomas
NPI 1801318993
$3,230.68
in general payments reported to CMS, 2019-2025
27 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,997 · 2022: $739 · 2024: $217 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.02 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $275.25 | 2021-2025 | Enhertu |
| Novo Nordisk INC | $264.16 | 2021-2022 | |
| Astellas Pharma US INC | $208.14 | 2021-2022 | |
| Lilly USA, LLC | $207.87 | 2021-2022 | |
| Daiichi Sankyo INC. | $197.23 | 2021-2025 | Vanflyta, Enhertu |
| Biohaven Pharmaceuticals, INC. | $192.85 | 2021 | |
| Amarin Pharma, INC. | $161.28 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $159.12 | 2021-2024 | Keytruda, Lynparza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.22 | 2025 | Opdivo |
| Janssen Pharmaceuticals, INC | $104.92 | 2021 | |
| Pfizer INC. | $85.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.75 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.10 | 2024 | |
| Glaxosmithkline, LLC. | $47.49 | 2021-2022 | |
| Tempus Ai, INC | $47.40 | 2024 | |
| Vistapharm, INC. | $37.44 | 2021 | |
| Esperion Therapeutics, INC. | $31.66 | 2021 | |
| Gilead Sciences, INC. | $30.80 | 2025 | Trodelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2021-2022 | |
| Abbott Laboratories | $24.39 | 2022 | |
| Stryker Corporation | $18.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.